Nebulisers deliver drugs in aerosol format. They are typically used by 300 million people who suffer from conditions such as chronic obstructive pulmonary disease or cystic fibrosis. Effective delivery of medication is crucially dependent upon the droplet size distribution. Large drops are caught in the upper respiratory tract, while smaller ones are exhaled before they can be adsorbed – neither reach the patient.
Acu-Flow Limited (trading as Nebu~Flow) is developing the next generation of nebulisers. Their Nebu~Flow technology unlocks the delivery of next-generation inhaled drugs and the efficiency of delivery of hard-to-nebulise medicines.
Dr Elijah Nazarzadeh, managing director, has developed the Nebu~Flow technology and led business development and fundraising activities. Elijah joined the Shott Scale up Accelerator to strengthen his leadership skills in areas such as negotiations and strategy. This will help him to manage a growing team as the company scales and extends its product range. The Shott Scale up Accelerator and mentoring programme will also enable him to expand his network and learn skills required to take the company through the series-A investment round.
The company is going through a rapid growth stage and is currently developing its nebuliser product to gain regulation for inhalation drug delivery within the next three years. It is then looking to partner with pharmaceutical companies to develop drug–device combination products. The Nebu~Flow technology can be adopted for a wide range of applications and will help it to enter new markets, as it grows.
Associated Programme
